This site is intended for healthcare professionals
Search

Find disease awareness content and relevant supporting materials

Learning Zone 321 Events 31 News 17021 Drugs 62460 Trials 8003 Guidelines 825 Journals 3403
Filter results
Sort by:
Relevance
to
Latest drug news
Drug news
03/09/13

Study shows no CV risk with Nesina/Vipidia for Type 2D

Results of the EXAMINE cardiovascular (CV) safety outcomes trial testing Nesina/Vipidia (alogliptin), from Takeda, show alogliptin does not increase CV...

  • 1 min read
EMC Drug Feed
Drug information
01/02/22

Vipidia 6.25mg, 12.5mg, 25mg film-coated tablets

Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

  • 1 min read
FDA Hero Banner - Multi-coloured pills and tablets
Drug information
06/12/22

Alogliptin ALOGLIPTIN BENZOATE 6.25 mg/1 Padagis Israel Pharmaceuticals Ltd

  • 1 min read
FDA Hero Banner - Multi-coloured pills and tablets
Drug information
25/10/22

Alogliptin ALOGLIPTIN BENZOATE 25 mg/1 A-S Medication Solutions

  • 1 min read
FDA Hero Banner - Multi-coloured pills and tablets
Drug information
27/02/23

Alogliptin ALOGLIPTIN BENZOATE 25 mg/1 Aphena Pharma Solutions - Tennessee, LLC

  • 1 min read
FDA Hero Banner - Multi-coloured pills and tablets
Drug information
10/12/22

Alogliptin ALOGLIPTIN BENZOATE 12.5 mg/1 Aphena Pharma Solutions - Tennessee, LLC

  • 1 min read
Latest drug news
Drug news
11/03/15

Post Hoc analysis of EXAMINE trial for Nesina (alogliptin) showed no increased risk of heart failure risk- Takeda

Takeda Pharmaceutical Company Limited announced that a post hoc analysis of data from the global EXAMINE (EXamination of CArdiovascular OutcoMes:...

  • 1 min read
Latest drug news
Drug news
25/11/11

Takeda re-files Nesina at the FDA for Type 2 Diabetes

Takeda has re-filed applications for Nesina (alogliptin) as a monotherapy and alogliptin plus pioglitazone at the FDA following a Complete...

  • 1 min read
FDA Hero Banner - Multi-coloured pills and tablets
Drug information
06/12/22

Alogliptin ALOGLIPTIN BENZOATE 25 mg/1 Padagis Israel Pharmaceuticals Ltd

  • 1 min read
FDA Hero Banner - Multi-coloured pills and tablets
Drug information
06/12/22

Alogliptin ALOGLIPTIN BENZOATE 12.5 mg/1 Padagis Israel Pharmaceuticals Ltd

  • 1 min read
See more